- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05028504
A Phase II Study of Anlotinib Combined With Penpulimab in Subjects With Gynecological Cancer (ALTER-GO-020)
December 25, 2023 updated by: Guonan Zhang, Sichuan Cancer Hospital and Research Institute
A Single-arm, Open-label, Multi-cohort, Multi-center Phase II Clinical Study of Anlotinib Combined With Penpulimab in the Treatment of Recurrent or Metastatic Gynecological Cancer
This is a single-arm, open-label, phase II clinical trial to evaluate the efficacy and safety of penpulimab combined with anlotinib in subjects with gynecological cancer, including 23 ovarian cancer,37 endometrial cancer,26 cervical cancer.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
86
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Guonan Zhang
- Phone Number: 86-13881866599
- Email: zhanggn@hotmail.com
Study Contact Backup
- Name: Hong Liu
- Phone Number: 86-13693447854
- Email: liuhaotian12@163.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100730
- Recruiting
- Peking Union Medical College Hospital
-
Contact:
- Yang Xiang
- Phone Number: 010-69156068
- Email: XiangY@pumch.cn
-
Sub-Investigator:
- Ninghai Cheng
-
-
Guangdong
-
Guangdong, Guangdong, China, 510080
- Recruiting
- The First Affiliated Hospital, Sun Yat-sen University
-
Contact:
- Mian He
- Phone Number: 86-13719000300
-
Sub-Investigator:
- Peng Guo
-
-
Hefei
-
Hefei, Hefei, China
- Recruiting
- The First Affiliated Hospital of USTC, Anhui Provincial Hospital
-
Contact:
- Weidong Zhao
- Phone Number: 86-13955105591
-
Sub-Investigator:
- Zhengzheng Chen
-
-
Shanxi
-
Xi'an, Shanxi, China
- Recruiting
- Shaanxi Provincial People's Hospital
-
Contact:
- Lihong Chen
- Phone Number: 86-13689280015
-
Sub-Investigator:
- Fen Li
-
Xi'an, Shanxi, China
- Not yet recruiting
- Shaanxi Provincial Cancer Hospital
-
Contact:
- Guoqing Wang
- Phone Number: 86-13892828647
-
Sub-Investigator:
- Lijuan Hu
-
-
Sichuan
-
Chengdu, Sichuan, China, 610000
- Recruiting
- Sicchuan cancer hospital
-
Sub-Investigator:
- Hong Liu
-
Contact:
- Hong Liu
- Phone Number: 86-13693447854
-
Contact:
- Guonan Zhang
- Phone Number: 86-13881866599
- Email: zhanggn@hotmail.com
-
Sub-Investigator:
- Dengfeng Wang
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Understood and signed an informed consent form;
- 18 years and older, female, Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1, life expectancy ≥3 months;
- Histopathologically confirmed epithelial ovarian, fallopian tube, or primary peritoneal cancer; or endometrial cancer; or cervical cancer (including squamous cell, adenocarcinoma, or adenosquamous cell carcinoma);
Patients must also meet any of the following conditions:
- Platinum-resistant relapsed or platinum-refractory ovarian cancer, the patient has received at least 1 line of platinum-based chemotherapy after previous cytoreductive surgery;
- With residual disease after surgery or inoperable stage III-IV endometrial cancer, and refused to receive chemoradiation/radiation/chemotherapy; or recurrent endometrial cancer unsuitable or refusing standard therapy;
- Persistent cervical cancer unsuitable for curative treatment, or recurrent/metastatic cervical cancer that refuses to receive standard treatment (for recurrent disease, not yet treated).
- At least one measurable lesion according to the RECIST 1.1;
- Try to provide tumor tissue samples for PD-L1 testing (not required);
Demonstrates adequate organ function:
- Blood routine inspection: Hemoglobin (HB) >= 90 g/L; The absolute value of neutrophil (ANC) >= 1.5x10^9/L;Platelets (PLT) >= 100x10^9/L;
- Blood biochemical inspection: Serum creatinine (Cr) <= 1.5 ULN, or creatinine clearance (CCr) >= 60mL / min; Total bilirubin (TBIL) <= 1.5 ULN, or direct bilirubin <= 1.0 ULN; AST and ALT <= 2.5 ULN.
- Blood coagulation function: Activated partial thromboplastin time, international standardized ratio adn prothrombin time <=1.5 ULN;
- Cardiac Function: left ventricular ejection fraction (LVEF) >=50%;
- Women of child-bearing potential must agree to use contraceptive measures (such as intrauterine devices or condoms) during the study and for 6 months after the end of the study, and have a negative serum pregnancy test within 7 days of enrollment, and must be non lactating subjects.
Exclusion Criteria:
- Has other non-epithelial ovarian tumors or borderline ovarian epithelial tumors; has carcinosarcoma, endometrial leiomyosarcoma, endometrial stromal sarcoma, or other high-grade sarcoma; has small cell carcinoma of the cervix, or clear cell carcinoma;
- Other malignant tumors that have appeared or are currently present within 5 years, except for cured cervical carcinoma in situ, non-melanoma skin cancer and superficial bladder tumors;
- Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g. cytotoxic T-lymphocyte-associated protein 4 [CTLA-4], OX 40, CD137);
- Has received prior therapy with tyrosine kinase inhibitors that target VEGFR, such as pazopanib, sorafenib, regorafenib, apatinib and other drugs; but previous bevacizumab treatment is allowed (only for ovarian cancer cohorts), provided that the treatment is stopped for more than 4 weeks before enrollment;
- Has received prior radiotherapy within 4 weeks prior to enrollment (participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis - a 2-week washout is permitted for palliative radiation to non-CNS disease and vaginal brachytherapy);
- Has received prior hormonal therapy for the treatment of endometrial carcinoma within 1 week before enrollment;
- Expect to use any active vaccine against infectious diseases (such as influenza vaccine, chickenpox vaccine, etc.) within 28 days before the first dose or during the study period;
- Patients received systemic glucocorticoid therapy or other immunosuppressive therapy (dose> 10mg / day prednisone or other effective hormones) within 14 days before the first dose;
- Active autoimmune diseases that require systemic treatment have occurred within 2 years before the first dose;
- Subjects known to be allergic to the study drug or any of its excipients or have experienced a severe allergic reaction to other monoclonal antibodies;
- Has uncontrollable symptoms of brain metastases, spinal cord compression, cancerous meningitis;
- Has any bleeding or bleeding event ≥ CTC AE Grade 3 or unhealed wounds, ulcers or fractures within 4 weeks before enrollment;
- Patients with a clear tendency to gastrointestinal bleeding;
- Suspected or definite presence of symptoms or signs of radiation enteritis, and recurrence within 1 year from the end of radiotherapy;
- Patients whose tumors have invaded large blood vessels or poorly demarcated from the blood vessels according to imaging findings (CT/MRI);
- Prophylactic use of low dose aspirin (≤100mg/d) and low molecular weight heparin (≤40mg/d) is permitted in patients undergoing thrombolysis or anticoagulant therapy;
- Has clinically significant thyroid dysfunction before enrollment;
- Has multiple factors affecting oral medication (such as inability to swallow, chronic diarrhea and intestinal obstruction);
Has any severe acute complications before enrollment:
- Blood pressure control is not ideal (systolic pressure >= 150 mmHg, diastolic pressure >= 100 mmHg);
- Patients had Unstable angina pectoris, myocardial infarction, ≥grade 2 congestive heart failure, or arrhythmia requiring treatment (including QTc ≥480 ms) within 6 months before enrollment;
- Active or uncontrolled serious infection (≥CTC AE grade 2 infection);
- Epidemiological test results during the screening period showed that any of the following is met: * HBsAg positive and HBV DNA exceeds the upper limit of normal value (those who fall within the normal range after antiviral treatment can be included); * Anti-HCV positive and HCV RNA positive; * HIV positive;
- Poorly controlled diabetes (fasting blood glucose ≥ grade 2);
- Had an arterio / venous thrombotic / carcinothrombotic event within 6 months, such as cerebrovascular accident (including transient ischemic attack, intracerebral hemorrhage, cerebral infarction), deep vein thrombosis, pulmonary embolism, and Hypertensive crisis or hypertensive encephalopathy;
- Exacerbated chronic obstructive pulmonary disease (COPD) or other respiratory diseases that require hospitalization, or have active lung infections and/or acute bacterial or fungal infections that require intravenous antibiotic treatment within 28 days before the first dose.
- Has participated in other anti-tumor intervention clinical trials within 4 weeks before the first medication;
- According to the judgement of the researchers, there are other factors that may lead to the termination of the study. For example, other serious diseases including mental disorders need to be treated together, serious laboratory abnormalities, accompanied by family or social factors, which will affect the safety of the subjects, or the collection of data and samples.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Penpulimab+Anlotinib
Penpulimab 200 mg IV on Day 1 of each 21-day cycle plus Anlotinib capsules 12mg given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
|
Penpulimab is a humanized monoclonal antibody targeting programmed cell death-1 (PD-1), which prevents PD-1 from binding to PD-L1 and PD-L2 receptors on tumor cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
A multi-target receptor tyrosine kinase inhibitor
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (ORR)
Time Frame: up to 96 weeks
|
Percentage of Participants Achieving Complete Response (CR) and Partial Response (PR)
|
up to 96 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression free survival (PFS)
Time Frame: up to 96 weeks
|
PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause.
|
up to 96 weeks
|
Duration of Response (DOR)
Time Frame: up to 96 weeks
|
Time from tumor first assessment to CR or PR to first assessment to PD (Progressive Disease) or death from any cause
|
up to 96 weeks
|
Disease control rate(DCR)
Time Frame: up to 96 weeks
|
Percentage of Participants Achieving Complete Response (CR) and Partial Response (PR) and Stable Disease (SD).
|
up to 96 weeks
|
Overall Survival (OS)
Time Frame: up to 120 weeks
|
OS defined as the time from randomization to death from any cause.
Participants who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive.
|
up to 120 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Guonan Zhang, Sichuan Cancer Hospital and Research Institute
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 10, 2022
Primary Completion (Estimated)
December 31, 2024
Study Completion (Estimated)
December 31, 2025
Study Registration Dates
First Submitted
August 25, 2021
First Submitted That Met QC Criteria
August 25, 2021
First Posted (Actual)
August 31, 2021
Study Record Updates
Last Update Posted (Estimated)
December 27, 2023
Last Update Submitted That Met QC Criteria
December 25, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Other Study ID Numbers
- ALTERGO020
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gynecological Cancer
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownGynecological CancerChina
-
Lena NilssonCompleted
-
University of ChesterCompleted
-
Universiti Putra MalaysiaNot yet recruitingGynecological Cancer | Elective SurgeryMalaysia
-
Bakirkoy Dr. Sadi Konuk Research and Training HospitalCompletedThe Effect of Analgesia Methods Applied in Gynecological Cancer Surgeries on Postoperative AnalgesiaRegional Anesthesia Morbidity | Gynecological Cancer SurgeryTurkey
-
Rajavithi HospitalRecruitingPostoperative Outcomes | Whey Protein | Gynecological Cancer SurgeryThailand
-
University Hospital, BordeauxCompleted
-
Centre Francois BaclesseLigue contre le cancer, FranceRecruitingLong Term Cancer Side Effects | Supportive Care in Cancer | Cancer Survivorship Care Plan | Advanced Nurse Practitioner | Pelvic Gynecological CancerFrance
-
Pusan National University Yangsan HospitalRecruitingGynecological SurgeryKorea, Republic of
-
Institute of Oncology LjubljanaRecruiting
Clinical Trials on Penpulimab
-
Hunan Cancer HospitalFuzhou Pulmonary Hospital of Fujian; Chia Tai Tianqing Pharmaceutical Group...RecruitingSmall Cell Lung CancerChina
-
Hunan Cancer HospitalHenan Cancer Hospital; Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingNon Small Cell Lung CancerChina
-
Sun Yat-sen UniversityNot yet recruiting
-
Peking Union Medical College HospitalRecruitingPheochromocytoma, Metastatic | Paraganglioma, Malignant | Pheochromocytoma MalignantChina
-
Zhongda HospitalRecruiting
-
Peking Union Medical College HospitalRecruiting
-
Peking Union Medical College HospitalNot yet recruitingLocally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid CarcinomaChina
-
Sun Yat-sen UniversityChia Tai Tianqing Pharmaceutical Group Co., Ltd.Recruiting
-
The First Affiliated Hospital of Xinxiang Medical...RecruitingLung Cancer | Non Small Cell Lung Cancer | Lung Carcinoma | Non-small Cell Carcinoma | Lung NeoplasmChina
-
The First Affiliated Hospital of Zhengzhou UniversityNot yet recruitingCervical Cancer